Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867804 | 0.91 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23969823 | 0.88 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24462730 | 0.86 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL23867807 | 0.86 | TAS1R3 (0.34) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5407861 | 0.82 | — | — | |
| SCHEMBL5587657 | 0.82 | LDHA (0.33) | — | |
| SCHEMBL23969822 | 0.80 | GABRA1 (0.30) | — | |
| SCHEMBL24611085 | 0.80 | GABRA1 (0.30) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12787573 | 0.79 | TAS1R3 (0.30) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12859001 | 0.77 | TAS1R3 (0.33) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011726-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011726-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | TAS1R3 3436/4885TAS1R1 2952/4885TAS1R2 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.